为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!

LY2784544,JAK2抑制剂, 酪氨酸蛋白激酶 JAK2 抑制剂

规格或纯度: ≥98%
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
L126490-5mg
5mg 现货 Stock Image
L126490-10mg
10mg 现货 Stock Image
L126490-50mg
50mg 期货 Stock Image

基本描述

英文别名 GANDOTINIB|1229236-86-5|LY2784544|LY 2784544|LY-2784544|Gandotinib (LY2784544)|3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine|Gandotinib [USAN]|Gandotinib(LY2784544)|ANC71R916O|Gandoti
规格或纯度 ≥98%
英文名称 LY2784544
生化机理 LY2784544 is identified as being highly selective inhibitor of JAK2 mutant V617F and has advanced into human clinical trials for the treatment of several myeloproliferative disorders.
储存温度 -20°C储存
运输条件 超低温冰袋运输
备注 卖完停产,不再备货
产品介绍

LY2784544是一种有效的JAK2抑制剂,IC50为3 nM,作用于JAK2V617F有效,比作用于JAK1和JAK3选择性高8和20倍。Phase 2。A selective inhibitor of JAK2 mutant V617F.

LY2784544 is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2.
A selective inhibitor of JAK2 mutant V617F.

产品属性

ALogP 3.8

名称和标识符

IUPAC Name 3-[(4-chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholin-4-ylmethyl)imidazo[1,2-b]pyridazin-6-amine
INCHI InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30)
InChi Key SQSZANZGUXWJEA-UHFFFAOYSA-N
Canonical SMILES CC1=CC(=NN1)NC2=NN3C(=C(N=C3C(=C2)CN4CCOCC4)C)CC5=C(C=C(C=C5)Cl)F
Isomeric SMILES CC1=CC(=NN1)NC2=NN3C(=C(N=C3C(=C2)CN4CCOCC4)C)CC5=C(C=C(C=C5)Cl)F
PubChem CID 46213929
分子量 469.95

化学和物理性质

溶解性 DMSO 94 mg/mL (200.02 mM); Water <1 mg/mL (<1 mM); Ethanol 9 mg/mL (19.15 mM)

质检证书(COA)

质检报告(COA)

输入批号以搜索COA:

相关文档

质检报告COA

请输入批号:


产品问答

产品问答

登录提交问题 Hover me 请先登录再提交问题
您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

参考文献

1. Ma L, Clayton JR, Walgren RA, Zhao B, Evans RJ, Smith MC, Heinz-Taheny KM, Kreklau EL, Bloem L, Pitou C et al..  (2013)  Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F..  Blood Cancer J,  (13):  (e109).  [PMID:23584399]
2. Berdeja J, Palandri F, Baer MR, Quick D, Kiladjian JJ, Martinelli G, Verma A, Hamid O, Walgren R, Pitou C et al..  (2018)  Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms..  Leuk Res,  71  (13):  (82-88).  [PMID:30025280]